PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

 PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

PharmaShots Weekly Snapshots (September 27 – October 02, 2021)

BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma

Published: Oct 1, 2021 | Tags: BMS, EMA, MAA, Relatlimab, Nivolumab, Metastatic Melanoma

Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19

Published: Oct 1, 2021 | Tags: Merck, Ridgeback, Molnupiravir, P-III, MOVe-OUT Trial, COVID-19

Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021

Published: Oct 1, 2021 | Tags: Sanofi, Amlitelimab, KY1005, P-IIa, Study, Atopic Dermatitis, EADV 2021

Dermavant Presented Long-Term Results of Tapinarof in P-III PSOARING 3 Study for the Treatment of Plaque Psoriasis at EADV

Published: Oct 1, 2021 | Tags: Dermavant, Tapinarof, P-III, PSOARING 3 Study, Plaque Psoriasis, EADV

Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV

Published: Oct 1, 2021 | Tags: Novartis, Remibrutinib, LOU064, P-IIb, Study, Chronic Spontaneous Urticaria, EADV

Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates

Published: Oct 1, 2021 | Tags: Otsuka, Sumitomo Dainippon, Neuropsychiatric Compounds

Merck to Acquire Acceleron for ~$11.5B

Published: Sept 30, 2021 | Tags: Merck, Acquire, Acceleron, ~$11.5B

Eli Lilly Reports Results of Tirzepatide in P-III SURPASS-3 MRI Sub-Study for the Treatment of Type 2 Diabetes

Published: Sept 30, 2021 | Tags: Eli Lilly, Tirzepatide, P-III, SURPASS-3 MRI Sub-Study, Type 2 Diabetes

Takeda Signs an Exclusive License Agreement with JCR to Commercialize JR-141 for the Treatment of Hunter Syndrome

Published: Sept 30, 2021 | Tags: Takeda, JCR, JR-141, Hunter Syndrome

TransMedics’ OCS Liver System Receives the US FDA’s Approval for Liver Transplantation

Published: Sept 30, 2021 | Tags: TransMedics, OCS Liver System, US, FDA, Approval, Livers Transplantation

Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus

Published: Sept 30, 2021 | Tags: Janssen, P-III, EVERGREEN Study, RSV Vaccine, Lower Respiratory Tract Disease, Respiratory Syncytial Virus

Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM

Published: Sept 30, 2021 | Tags: Regeneron, REGEN-COV, casirivimab, imdevimab, P-III, Trial, COVID-19, NEJM

Medtronic’s Radial Artery Catheter Device Receives CE Mark Approval for the Treatment of Neurovascular Diseases

Published: Sept 29, 2021 | Tags: Medtronic, Radial Artery Catheter Device, CE Mark, Approval, Neurovascular Diseases

Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria

Published: Sept 29, 2021 | Tags: Novartis, ligelizumab, QGE031, P-IIb, Study, Chronic Spontaneous Urticaria

ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021

Published: Sept 29, 2021 | Tags: ViiV Healthcare, Dovato, dolutegravir, lamivudine, P-III, TANGO Study, HIV, IDWeek 2021

AstraZeneca to Acquire Caelum for ~500M

Published: Sept 29, 2021 | Tags: AstraZeneca, Acquire, Caelum, ~500M

AbbVie’s Qulipta (atogepant) Receives the US FDA’s Approval for the Treatment of Migraine

Published: Sept 29, 2021 | Tags: AbbVie, Qulipta, atogepant, US, FDA, Approval, Migraine

The US FDA Approves New Indication for Lilly’s Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation

Published: Sept 29, 2021 | Tags: Lilly, Erbitux, cetuximab, Braftovi, encorafenib, US, FDA, Approval, Metastatic Colorectal Cancer, BRAF V600E Mutation

Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies

Published: Sept 28, 2021 | Tags: Boehringer Ingelheim, Invetx, Veterinary Therapies

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

Published: Sept 28, 2021 | Tags: ViiV Healthcare, Shionogi, S-365598, HIV

Eisai Initiates Rolling Submission of BLA to the US FDA for Lecanemab to Treat Alzheimer’s Disease

Published: Sept 28, 2021 | Tags: Eisai, BLA, US, FDA, Lecanemab, Alzheimer’s Disease

AstraZeneca’s Saphnelo (anifrolumab) Receives MHLW’s Approval for the Treatment of Systemic Lupus Erythematosus

Published: Sept 28, 2021 | Tags: AstraZeneca, Saphnelo, anifrolumab, MHLW, Approval, Systemic Lupus Erythematosus

Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Published: Sept 28, 2021 | Tags: Innovent, Union, Orismilast, Inflammatory Dermatology Conditions

Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies

Published: Sept 28, 2021 | Tags: Bio-Thera, Intract, Soteria, Phloral, Antibody Therapies

Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases

Published: Sept 27, 2021 | Tags: Incyte, Syndax, Axatilimab, cGVHD, Fibrotic Diseases

Takeda’s Alofisel (darvadstrocel) Receives MHLW’s Approval for the Treatment of Complex Perianal Fistulas with Non-active or Mildly Active Luminal CD

Published: Sept 27, 2021 | Tags: Takeda, Alofisel, darvadstrocel, MHLW, Approval, Complex Perianal Fistulas, Active Luminal CD

Astellas and Seagen’s Padcev (enfortumab vedotin) Receive MHLW’s Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Published: Sept 27, 2021 | Tags: Astellas, Seagen, Padcev, enfortumab vedotin, MHLW, Approval, Advanced Urothelial Cancer

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

Published: Sept 27, 2021 | Tags: JW, Relmacabtagene Autoleucel, P-II, RELIANCE Study, R/R LBCL, CSCO 2021

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

Published: Sept 27, 2021 | Tags: Innovent, AnHeart, Taletrectinib, AB-106, P-II, TRUST Trial, ROS1-Positive NSCLC, CSCO 2021

Amgen’s Repatha (evolocumab) Receives the US FDA’s Approval for the Treatment of Heterozygous Familial Hypercholesterolemia

Published: Sept 27, 2021 | Tags: Amgen, Repatha, evolocumab, US, FDA, Approval, Heterozygous Familial Hypercholesterolemia

Related Post: https://pharmashots.com/64800/pharmashots-weekly-snapshots-september-20-24-2021/

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post